ESSA Pharma (EPIX)
(Delayed Data from NSDQ)
$5.21 USD
-0.18 (-3.34%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $5.26 +0.05 (0.96%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for ESSA Pharma Inc falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 32 | 37 | 37 | 24 | 13 |
Income After Depreciation & Amortization | -32 | -37 | -37 | -24 | -13 |
Non-Operating Income | 6 | 2 | 0 | 0 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -27 | -35 | -37 | -24 | -10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -27 | -35 | -37 | -23 | -10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -27 | -35 | -37 | -23 | -10 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -32 | -37 | -37 | -24 | -13 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -32 | -37 | -37 | -24 | -13 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 44.09 | 44.04 | 38.48 | 22.44 | 8.43 |
Diluted EPS Before Non-Recurring Items | -0.60 | -0.80 | -0.96 | -1.04 | -1.46 |
Diluted Net EPS (GAAP) | -0.60 | -0.80 | -0.96 | -1.04 | -1.24 |
Fiscal Year end for ESSA Pharma Inc falls in the month of September.
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 8.63 | 10.50 | 7.60 | 7.16 | 8.91 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.63 | -10.50 | -7.60 | -7.16 | -8.91 |
Non-Operating Income | 1.40 | 1.50 | 1.63 | 1.67 | 1.61 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -7.23 | -8.99 | -5.96 | -5.48 | -7.30 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.23 | -8.99 | -5.96 | -5.48 | -7.30 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.23 | -8.99 | -5.96 | -5.48 | -7.30 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 44.37 | 44.24 | 44.13 | 44.09 | 44.09 |
Diluted EPS Before Non-Recurring Items | -0.16 | -0.20 | -0.14 | -0.12 | -0.17 |
Diluted Net EPS (GAAP) | -0.16 | -0.20 | -0.14 | -0.12 | -0.17 |